Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
First People's Hospital of Hangzhou
An observational, non-interventional, multi-central study of comparison of the frequency and abundance of T790M mutation using both amplification refractory mutation system (ARMS) and digital droplet PCR (ddPCR) methods among the different Clinical modes of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) failure
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed stage IIIB/IV NSCLC.
Investigator confirmed progression according RECIST 1.1 during EGFR-TKI treatment within 28 days of the enrollment
Activating mutation (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) in the EGFR gene or have had at least partial response with EGFR TKI lasting ≥ 6 months
Patient must be able to comply with the protocol
You may not be if
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined disease progression for more than 28 days while on previous EGFR-TKI treatment.
Patient has been treated with any investigational agent for any indication within 4 weeks of study treatment.
Histologically confirmed small cell lung cancer or other metastatic tumors
Patient with no histologic or cytological diagnosis.